Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
PHASE1
The purpose of this study was to evaluate the safety, tolerability, and eff...
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
PHASE1
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclo...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
PHASE1
Background:
Antibodies help the body fight infection. VRC01LS is an antibo...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
PHASE1
Background:
\- VRC01 is a manmade antibody directed against the human immu...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike